Receptor for advanced glycation end products - membrane type1 matrix metalloproteinase axis regulates tissue factor expression via RhoA and Rac1 activation in high-mobility group box-1 stimulated endothelial cells

PLoS One. 2014 Dec 9;9(12):e114429. doi: 10.1371/journal.pone.0114429. eCollection 2014.

Abstract

Background: Atherosclerosis is understood to be a blood vessel inflammation. High-mobility group box-1 (HMGB-1) plays a key role in the systemic inflammation. Tissue factor (TF) is known to lead to inflammation which promotes thrombus formation. Membrane type1 matrix metalloprotease (MT1-MMP) associates with advanced glycation endproducts (AGE) triggered-TF protein expression and phosphorylation of NF-κB. However, it is still unclear about the correlation of MT1-MMP and HMBG-1-mediated TF expression. In this study, we investigated the molecular mechanisms of TF expression in response to HMGB-1 stimulation and the involvement of MT1-MMP in endothelial cells.

Methods and results: Pull-down assays and Western blotting revealed that HMGB-1 induced RhoA/Rac1 activation and NF-kB phosphorylation in cultured human aortic endothelial cells. HMGB-1 increased the activity of MT1-MMP, and inhibition of RAGE or MT1-MMP by siRNA suppressed HMGB-1-induced TF upregulation as well as HMGB-1-triggered RhoA/Rac1 activation and NF-kB phosphorylation.

Conclusions: The present study showed that RAGE/MT1-MMP axis modified HMBG-1-mediated TF expression through RhoA and Rac1 activation and NF-κB phosphorylation in endothelial cells. These results suggested that MT1-MMP was involved in vascular inflammation and might be a good target for treating atherosclerosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis / pathology
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Enzyme Activation / drug effects
  • Gene Expression Regulation / drug effects
  • Gene Silencing
  • HMGB1 Protein / pharmacology*
  • Humans
  • Matrix Metalloproteinase 14 / deficiency
  • Matrix Metalloproteinase 14 / genetics
  • Matrix Metalloproteinase 14 / metabolism*
  • NF-kappa B / metabolism
  • Phosphorylation / drug effects
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / metabolism*
  • Signal Transduction / drug effects
  • Thromboplastin / metabolism*
  • rac1 GTP-Binding Protein / metabolism*
  • rhoA GTP-Binding Protein / metabolism*

Substances

  • HMGB1 Protein
  • NF-kappa B
  • RNA, Small Interfering
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • Thromboplastin
  • Matrix Metalloproteinase 14
  • rac1 GTP-Binding Protein
  • rhoA GTP-Binding Protein

Grants and funding

This work was supported by the Japan Society for the Promotion of Science (No. 22790718 to KS) (http://www.jsps.go.jp/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.